About : Concepts : Treatment : Redlog News : Contact Us

Topical Rosacea Treatments

Cleanse and De-Sensitize





Ocular Rosacea

Shop Online

View Cart/Checkout

List of All Products

New Treatment Topics

What Is Flushing?

Prevent Flushing

Reduce Redness


Skin Barrier Repair

Shampoo Worsening Rosacea

Skin Aging and Glycation

Senetek Initiates Clinical Trials of Pyratine 6 for Acne Rosacea [April 2007]

NAPA, California, April 11, 2007 -- Senetek PLC (OTCBB:SNTKY), www.senetekplc.com, a life sciences product development company targeting the science of aging, has initiated clinical trials of its Pyratine 6 compound (PRK 124) for Acne Rosacea after evaluating positive results from a comparison of separate clinical trials of Pyratine 6 and Kinetin, Senetek's original anti-aging active ingredient.

An independent comparative analysis evaluated the effectiveness of Senetek's second-generation patented cytokinin, Pyratine 6 (PRK 124) relative to its original anti-aging active ingredient, Kinetin. The analysis compared results of separate clinical studies conducted at the University of California, Irvine (Kinetin) and at the independent research laboratory RCTS, Inc. in Irving, Texas (Pyratine 6). The subjects in the Pyratine 6 clinical trial scored significantly higher on each measure than those in the Kinetin study throughout the 12 weeks of evaluation. In some measures the comparison was particularly notable, such as fine wrinkles (22% improvement with Pyratine 6 vs. 2% improvement with Kinetin after eight weeks), skin roughness (86% improvement with Pyratine 6 vs. 35% improvement with Kinetin after eight weeks) and overall skin aging (24% vs. 3% after eight weeks).

The Pyratine 6 study also featured additional evaluative methodologies not included in the Kinetin study, such as the NOVA Dermal Phase Meter for measuring the skin's moisture content, and expert evaluations of reductions in erythema (redness) and acne lesions. The NOVA apparatus measured increases in skin moisture content of 35% and 41% after eight and twelve weeks, respectively. The evaluations found 42% and 62% reductions in erythema after two and four weeks, respectively, and a 45% reduction in acne lesions after twelve weeks. Pyratine 6 was well tolerated by all subjects, producing no measurable skin irritation or signs of allergic contact dermatitis with twice-daily application over the 12 week study period.

Frank Massino, Chief Executive Officer of Senetek commented, "The data collected through the comparative analysis of Pyratine 6 and Kinetin has given us significant reason to focus our efforts on taking the strategic steps necessary to launch Pyratine 6 commercially as an anti-aging compound as well as initiate clinical trials to prove that Pyratine 6 can also be used as an effective treatment for Acne Rosacea. Following our success with Kinetin, we are excited about the potential for Pyratine 6 as it presents yet another valuable opportunity for our Company. "

Enrollment has begun on the new Senetek sponsored Institutional Review Board (IRB)-approved pilot clinical study of Pyratine 6 for treatment of Rosacea, to be conducted at the University of California at Irvine. The comparative analysis results also have influenced one of the Company's prospective licensees, a major cosmetic company, to commence separate clinical trials of Pyratine 6 for Acne Rosacea and for skin whitening.

Acne Rosacea is a common chronic dermatosis characterized by inflammatory lesions and persistent erythema (redness) conservatively estimated to afflict some 16 million people in the U.S. and 45 million people worldwide. Acne Rosacea is currently primarily treated with oral antibiotics such as tetracycline and erythromycin and topical antibiotics such as metronidazole, which involve long-term tolerability and other health concerns.

About Senetek PLC

Senetek is a life sciences-driven product development and licensing company with a portfolio of intellectual properties targeting the science of aging, including skincare and dermatological therapeutics, erectile dysfunction and nutrition. Senetek holds patents on the use of Kinetin and its analog Zeatin, naturally occurring cytokinins that have proven effective in improving the appearance of aging skin with virtually none of the side effects associated with acid-based active ingredients, which it has licensed to Valeant Pharmaceuticals International, and on a number of second generation cytokinins and other plant-derived compounds. Senetek's researchers at the University of Aarhus in Denmark also are collaborating with a broad range of academic and government-based research enterprises, including The Institute of Experimental Botany of the Czech Academy of Sciences, and with the Department of Dermatology, University of California at Irvine, to identify and evaluate additional new biologically active compounds for this high growth field. In addition, Senetek has entered into exclusive licenses for Europe and North America, respectively, for its patented combination drug treatment for erectile dysfunction, Invicorp®, has an exclusive manufacturing distributorship for its proprietary diagnostic monoclonal antibodies, and recently sold, with retained rights of profit participation, its patented drug delivery system, Reliaject®.

For additional information, please visit Senetek PLC's Web site at http://www.senetekplc.com.

Contact Information:

Senetek PLC: 707-226-3900 ext. 102


The Investor Relations Group: 212-825-3210

Jordan Silverstein/Christine Berni (Investor Relations)

Lyn Granito (Public Relations)

Safe Harbor Statement:

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act, including those that might imply commercial potential and successful evaluation and development of new compounds. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K/A for the year 2005. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

Author: Peter Wilson.

Reviewed: Friday, 7 May 2010.

Further Information: Faultless Hydration [April 2007] : Bakel Skin Care : Basal Cell Carcinoma (Skin Cancer) & Rhinophyma [April 2007] : Rosacea: A Potential Complication of Skin Cancer Removal [April 2007] : Cycling Hormones and Female Skin Behaviour [April 2007] : Variable-Pulse Nd:YAG Laser in the Treatment of Facial Telangiectasias (Broken Capillaries) [April 2007] : Senetek Initiates Clinical Trials of Pyratine 6 for Acne Rosacea [April 2007] : New RosaTox Forté Firming Soothing Mask [March 2007] : More on Metronidazole (Metro Gel/Lotion/Cream) :


Rosacea Mobile Site

Rosacea News

March 2016

February 2016

January 2016

December 2015

June 2014

May 2014

April 2014

March 2014

February 2014

January 2014

December 2013

November 2013

October 2013

September 2013

August 2013

July 2013

June 2013

May 2013

April 2013

November 2012

August 2012

April 2012

July 2011

June 2011

May 2011

September 2010

August 2010

July 2010

June 2010

May 2010